Sagimet Biosciences Inc. (SGMT)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Sagimet Biosciences Inc. (SGMT) is up 14.7% since the beginning of the year. At $7 per share, SGMT is trading 40.5% below its 52-week high of $11.

Sagimet Biosciences Inc. (SGMT) has returned 14.70% so far this year and 87.05% over the past 12 months.

Based on dividend-adjusted daily data since Jul 14, 2023, SGMT's average daily return is +0.23%, while the average monthly return is +2.62%. At this rate, an investment would double in approximately 2.2 years.

Historically, 39% of months were positive and 61% were negative. The best month was Jun 2025 with a return of +114.7%, while the worst month was Oct 2023 at -58.4%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 4 months.

On a daily basis, SGMT closed higher 46% of trading days. The best single day was Jan 22, 2024 with a return of +170.1%, while the worst single day was Feb 6, 2024 at -30.4%.

Sagimet Biosciences Inc. has an annualized alpha of 17.54%, beta of 2.13, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since July 17, 2023.

• This stock participated in 320.69% of S&P 500 Index downside but only 139.08% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

SGMT ranks 71 for risk / return — better than 71% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Sagimet Biosciences Inc. (SGMT) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Sagimet Biosciences Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Sagimet Biosciences Inc. was 89.69%, occurring on Apr 8, 2025. The portfolio has not yet recovered.

The current Sagimet Biosciences Inc. drawdown is 63.14%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Sagimet Biosciences Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Sagimet Biosciences Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.